The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Tyrosinemia type 1 ? complex splicing defects and a missense mutation in the fumarylacetoacetase gene
Abstract
Two mutations are reported in six tyrosinemia type 1 patients from northern Europe. In four patients, a G to A transition at nucleotide position 1009 (G1009-->A) of the fumarylacetoacetase (FAH) coding sequence caused aberrant splicing by introducing an acceptor splice site within exon 12, thereby deleting the first 50 nucleotides of this exon. The following exon-intron boundary was frequently missed, and a cryptic donor splice site within intron 12 caused a partial intron 12 retention of 105 bp. This point mutation alternatively gave a glycine 337 to serine substitution in instances of correct splicing. The mutation is rapidly detected by PvuII digestion of polymerase chain reaction (PCR)-amplified genomic DNA. Another mutation, g+5-->a in the intron 12 donor splice site consensus sequence (IVS12 g+5-->a), was found in five of the patients. This caused alternative splicing with retention of the first 105 nucleotides of intron 12, exon 12 skipping, and a combined deletion of exons 12 and 13. Rapid detection of this mutation is achieved by restriction digestion of PCR-amplified genomic DNA; a mismatch primer combined with the point mutation creates a Tru9I restriction site. One patient who was homozygous for the G1009-->A mutation had a chronic form of tyrosinemia. Three patients were combined heterozygotes for G1009-->A and IVS12 g+5-->a. Their clinical phenotypes varied from acute to chronic, indicating the impact of background genes and/or external factors on the presentati…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
At least 26 different mutations in FAH have been identified in HT1 patients, including missense, nonsense, and splice consensus site mutations.
“At least 26 different mutations in FAH have been identified in HT1 patients, including missense, nonsense, and splice consensus site mutations (5, 11–17).”
From Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1 (2001) · cites this paper as [13]
Citations
Cites
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 1×
“Recently, we showed that some HT1 patients had a mosaic pattern of immunoreactive FAH protein and enzyme activity in liver tissue ( Kvittingen et al. 1993 ).”
BackgroundSelf-citationPhaneuf, D., Lambert, M., Laframboise, R., Mitchell, G., Lettre, F., & Tanguay, R. M. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115979 · Cited by 84
Berger, R., Van Faassen, H., Taanman, J. W., De Vries, H., & Agsteribbe, E. (1987) · Pediatric Research · doi:10.1203/00006450-198710000-00005 · Cited by 37
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Aponte, J. L., Sega, G. A., Hauser, L. J., Dhar, M. S., Withrow, C. M., Carpenter, D. A., Rinchik, E. M., Culiat, C. T., & Johnson, D. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.641 · Cited by 68
Metadata
- Authors
- Rootwelt, H., Kristensen, T., Berger, R., H�ie, K., & Kvittingen, E.
- Affiliations
- University of Oslo (NO)
- Wilhelmina Children's Hospital (NL)
- Venue
- Human Genetics
- Published
- 1994-09
- Volume
- 94
- Issue
- 3
- Pages
- 235-9
- ISSN
- 0018-7348 (ISSN-L)
- 0340-6717
- 1432-1203
- OpenAlex
- W2008483689
- Cited by
- 23
- References
- 4
- Citations by year
- 2026: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2014: 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Human Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- tyrosinemia type I, aberrant splicing, missense mutations, cryptic splice site, exon skipping, alternative splicing, genotype-phenotype correlation
- MeSH terms
- Amino Acid Metabolism, Inborn Errors, Base Sequence, Child, Child, Preschool, Electrophoresis, Agar Gel, Exons, Female, Humans, Hydrolases, Infant, Male, Molecular Sequence Data, RNA Splicing, RNA, Messenger, Tyrosine, Polymerase Chain Reaction, Point Mutation, DNA Primers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review